Vireo Growth (VREOF) Liabilities from Discontinued Operations (2020 - 2025)
Vireo Growth (VREOF) posted Liabilities from Discontinued Operations of 89334872.0 for Q3 2025, little changed sequentially from 89379390.0 in Q2 2025, and up 1.02% YoY from 88437021.0 in Q3 2024.
Vireo Growth (VREOF) Liabilities from Discontinued Operations (2020 - 2025) Analysis & Trends
Vireo Growth has reported Liabilities from Discontinued Operations for 6 years, with the latest figure at 89334872.0 in Q3 2025.
- Quarterly Liabilities from Discontinued Operations rose 1.02% year-over-year to 89334872.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 89334872.0 (up 1.02% YoY) and the FY2024 annual result came in at 89387203.0, up 1.2% from the prior year.
- Liabilities from Discontinued Operations was little changed at 89334872.0 in Q3 2025 per VREOF's latest filing, from 89379390.0 in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at 89387203.0 in Q4 2024 and troughed at 116803.0 in Q3 2021.
- A 5-year average of 58887381.31 and a median of 81925789.0 in 2023 frame the typical range for Liabilities from Discontinued Operations.
- The sharpest annual moves came in 2023 and 2025: Liabilities from Discontinued Operations soared 6592.16% in 2023, then grew 1.02% in 2025.
- Over 5 years, Liabilities from Discontinued Operations stood at 116803.0 in 2021, then jumped by 1029.98% to 1319847.0 in 2022, then jumped by 6592.16% to 88326323.0 in 2023, then gained by 1.2% to 89387203.0 in 2024, then dropped by 0.06% to 89334872.0 in 2025.
- According to Business Quant data, Liabilities from Discontinued Operations over the past three periods registered 89334872.0, 89379390.0, and 89351157.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Vireo Growth | 491.44 Mn | 349.14 Mn | 95.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 89.33 Mn |
| Sep 30, 2025 | 89.33 Mn |
| Jun 30, 2025 | 89.38 Mn |
| Jun 30, 2025 | 89.38 Mn |
| Mar 31, 2025 | 89.35 Mn |
| Mar 31, 2025 | 89.35 Mn |
| Dec 31, 2024 | 89.39 Mn |
| Dec 31, 2024 | 89.39 Mn |
| Sep 30, 2024 | 88.44 Mn |
| Sep 30, 2024 | 88.44 Mn |
| Jun 30, 2024 | 88.41 Mn |
| Jun 30, 2024 | 88.41 Mn |
| Mar 31, 2024 | 88.37 Mn |
| Mar 31, 2024 | 88.37 Mn |
| Dec 31, 2023 | 88.33 Mn |
| Dec 31, 2023 | 88.33 Mn |
| Sep 30, 2023 | 75.44 Mn |
| Sep 30, 2023 | 75.44 Mn |
| Jun 30, 2023 | 75.15 Mn |
| Jun 30, 2023 | 75.15 Mn |